As October marks Breast Cancer Awareness Month 2026, medical experts are raising public awareness about a little-known but particularly aggressive form of breast cancer that often escapes early detection because it does not present with the classic warning symptom most people associate with the disease: a distinct breast lump.
Inflammatory breast cancer, a rare but deadly subtype of the disease, progresses far more rapidly than most common breast cancers, and its symptoms are easily confused with far less dangerous benign inflammatory conditions, explains Tina Hieken, M.D., a surgical oncologist at the Mayo Clinic Comprehensive Cancer Center. Unlike traditional forms of breast cancer that gradually develop into detectable lumps over months or years, inflammatory breast cancer can trigger noticeable changes in just a few short weeks.
The reason for these atypical symptoms lies in how the cancer grows: abnormal cancer cells block the lymphatic channels in the breast’s skin and soft tissue, leading to visible skin changes rather than a solid lump. These changes include discoloration that can range from pink and red to deep purple or bruise-like patches, unusual warmth in the affected breast, and a pitted, dimpled skin texture known as peau d’orange, which resembles the surface of an orange peel.
Because these symptoms mirror common inflammatory conditions, it is not uncommon for cases of inflammatory breast cancer to be misdiagnosed as cellulitis, mastitis, Paget’s disease of the breast, or other harmless conditions. The cost of delayed diagnosis is steep: while inflammatory breast cancer accounts for only 1 to 5 percent of all breast cancer diagnoses in the United States, it is responsible for roughly 10 percent of all breast cancer deaths, according to official cancer statistics.
Dr. Hieken emphasizes that any unexpected breast skin change, particularly among women who are not breastfeeding and have no other explanation for redness or inflammation, should be evaluated immediately by a licensed medical professional to rule out cancer. This rapid onset of symptoms, she notes, is one of the key features that sets inflammatory breast cancer apart from more common subtypes, where lumps typically develop gradually and skin changes only appear much later in disease progression.
When it comes to treating inflammatory breast cancer, the standard care pathway differs significantly from treatment protocols for more common breast cancers. Because of its high risk of spreading to distant organs or recurring after initial treatment, a three-pronged approach is standard. Treatment begins with systemic therapy, a whole-body treatment tailored to the specific biological subtype of the cancer, determined by markers such as estrogen receptor expression or HER2 protein overexpression. Systemic therapy is administered intravenously, and can fall into one of three categories: chemotherapy that targets rapidly dividing cancer cells, targeted therapy for tumors that overexpress the HER2 protein, or immunotherapy for triple-negative breast cancers that do not express either estrogen receptors or HER2, the rarest subtype of inflammatory breast cancer.
After successful initial systemic therapy, patients typically undergo surgery to remove the affected breast and nearby lymph nodes, followed by radiation therapy that targets the chest, armpit, and shoulder region. More common, slower-growing breast cancers often do not require all three of these treatment modalities, Dr. Hieken notes.
In recent years, the landscape of inflammatory breast cancer treatment has improved dramatically, with two key innovations driving better patient outcomes. The first major advance is the shift toward personalized, subtype-specific systemic therapy delivered at the start of treatment, a model that aligns with modern treatment protocols for non-inflammatory breast cancer. The second is the improvement in cross-sectional imaging, which allows clinicians to detect whether cancer has spread beyond the breast and regional lymph nodes before starting treatment, enabling more accurate care planning.
Particularly notable progress has been made for HER2-positive inflammatory breast cancer: the addition of two complementary drugs that work together to block the effects of HER2 protein overexpression has drastically improved patient outcomes. For patients who do not achieve a full response from initial systemic therapy, new post-surgery targeted therapies now provide additional treatment options. Radiation therapy has also seen improvements, with intensity-modulated radiotherapy (IMRT) planned using integrated CT imaging that allows clinicians to map the patient’s anatomy in three dimensions and personalize treatment to minimize side effects. Techniques such as guided breath-holding or positioning patients lying on their stomach further reduce damage to healthy surrounding tissue.
At Mayo Clinic, the approach to treating this aggressive cancer relies on cross-disciplinary collaboration, with medical oncologists, radiation oncologists, surgical oncologists, and radiologists working alongside genetic counselors, pathologists, social workers, physical and occupational therapists, psychotherapists, and integrative medicine specialists to deliver comprehensive, whole-person care to patients, while researchers continue to develop new treatment options to further improve outcomes.